UK markets closed

Shattuck Labs, Inc. (STTK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.96+0.05 (+0.72%)
At close: 04:00PM EST
6.96 0.00 (0.00%)
After hours: 04:01PM EST

Shattuck Labs, Inc.

1018 West 11th Street
Suite 100
Austin, TX 78703
United States
919 864 2700

Full-time employees59

Key executives

NameTitlePayExercisedYear born
Dr. Taylor H. Schreiber M.D., Ph.D.Co-Founder, CEO & Director526.11kN/A1980
Dr. Arundathy Nirmalini Pandite M.B.A., M.D.Chief Medical Officer583kN/A1959
Ms. Casi DeYoungChief Bus. Officer440.66kN/A1971
Mr. Andrew R. Neill M.B.A.Chief Financial OfficerN/AN/A1986
Conor RichardsonSr. Director of Fin. & Investor RelationsN/AN/AN/A
Dr. Abhinav A. Shukla Ph.D.Chief Technical OfficerN/AN/AN/A
Ms. Erin Ator Thomson J.D.Gen. CounselN/AN/A1980
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Corporate governance

Shattuck Labs, Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.